Heparin Induced Thrombocytopenia/Thrombosis

Visentin, Gian Paolo

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Heart, Lung, and Blood Institute (NHLBI)
• Type: Clinical Investigator Award (CIA) (K08)
• Project #: 1K08HL003464-01
• Application #: 2211730
• Study Section: Research Training Review Committee (RTR)
• Project Start: 1996-02-01
• Project End: 2001-01-31
• Budget Start: 1996-02-01
• Budget End: 1997-01-31
• Support Year: 1
• Fiscal Year: 1996

Institution

• Name: Bloodcenter of Wisconsin, Inc.
• City: Milwaukee
• State: WI
• Country: United States
• Zip Code: 53233

Publications

Visentin, G P; Moghaddam, M; Beery, S E et al. (2001) Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 138:22-31

Visentin, G P (1999) Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb Haemost 82:448-56

Peterson, J A; Visentin, G P; Newman, P J et al. (1998) A recombinant soluble form of the integrin alpha IIb beta 3 (GPIIb-IIIa) assumes an active, ligand-binding conformation and is recognized by GPIIb-IIIa-specific monoclonal, allo-, auto-, and drug-dependent platelet antibodies. Blood 92:2053-63

Suh, J S; Aster, R H; Visentin, G P (1998) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91:916-22